Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma

Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.

Related Keywords

Ohio ,United States ,James Isaacs ,Department Of Hematology ,Medical Oncology ,Cleveland Clinic ,Cleveland Clinic Gross Family Melanoma Registry ,Nivolumab ,Talazoparib ,Opdivo ,Talzenna ,Nivolumab Plus Talazoparib ,Melanoma ,Aacr Annual Meeting ,Brca ,